Alnylam presents positive Phase I ALN-PCS trial data

The RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia utilized Tekmira’s lipid nanoparticle (LNP) technology.

Tekmira president and CEO Mark Murray said the new data from the ALN-PCS human clinical trial continues to demonstrate that Tekmira’s LNP technology is well tolerated and enables RNAi activity in humans.

The study has demonstrated that administration of a single dose of ALN-PCS, in the absence of concomitant lipid-lowering agents such as statins, resulted in durable reductions of PCSK9 plasma levels of up to 84% and lowering of low-density lipoprotein cholesterol of up to 50%.

ALN-PCS was shown to be safe and well tolerated in the study.

"As the evidence of positive data within the RNAi field continues to grow, we believe that Tekmira’s LNP technology is a key driver advancing the field towards the commercialization of RNAi therapeutics for a variety of clinical indications," Murray added.